title: Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
abstract: p53 triple mutants (120N/121G/277H, 120H/121G/ 277H, 120S/121G/277H and 120H/121G/277Y) have altered sequence specificity in bandshift assays in vitro and transcription assays in vivo. These mutants activate transcription from the site TTT CATG AAA but not from wild type sites. The triple mutants activate more strongly than p53 with a single 277Y mutation. The TTT site matches the wild type p53 consensus at only 4/10 positions and is not recognised by wild type p53. 277Y mutations have been described in human tumours, and Ewing tumour cells expressing this mutant from the endogenous p53 locus selectively activate transcription from transfected luciferase reporters regulated by TTT-mutant p53 binding sites. p53 mutants with altered sequence specificity have potential advantages for cancer gene therapy: if used to activate transcription of conditionally toxic genes they would allow tumour-targeting by p53, which acts as a sensor for the malignant state, but place control over cell killing in the hands of the clinician. Rare tumours expressing such mutants from the endogenous p53 locus could be targeted directly with p53-regulated suicide vectors, but for most tumours both the p53 mutant and the reporter would need to be encoded by the virus.
authors.affiliation: Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Gagnebin
authors.forename: H
authors.initials: H
authors.lastname: Kovar
authors.forename: A V
authors.initials: AV
authors.lastname: Kajava
authors.forename: A
authors.initials: A
authors.lastname: Estreicher
authors.forename: G
authors.initials: G
authors.lastname: Jug
authors.forename: P
authors.initials: P
authors.lastname: Monnier
authors.forename: R
authors.initials: R
authors.lastname: Iggo
mesh_terms: D001483:Base Sequence; D001665:Binding Sites; D016384:Consensus Sequence; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D017930:Genes, Reporter; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D008156:Luciferases / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D012512:Sarcoma, Ewing / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D013379:Substrate Specificity; D014158:Transcription, Genetic; D015533:Transcriptional Activation; D014161:Transduction, Genetic; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000378:metabolism*
chemical_list: D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53; D008156:Luciferases